TRIM21 and esophageal squamous cell carcinoma: To confirm whether Sorafenib's anti‐tumor activity in ESCC depends specifically on TRIM21, we performed rescue experiments using both in vitro CCK‐8 proliferation assays and in vivo subcutaneous xenograft models.